Navigation Links
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
Date:6/30/2008

- Product appears safe with no dose-limiting toxicities -

- Chemophase dose for pivotal trials successfully determined - - Halozyme to seek input from regulatory authorities in order to advance

into pivotal clinical program in 2009 -

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a status update for its continuing Phase I/IIa Chemophase(R) clinical trial in the treatment of superficial bladder cancer. Based on the results, the Chemophase combination treatment of mitomycin plus the recombinant human hyaluronidase (rHuPH20) enzyme was well tolerated and appears safe. The study reported no dose-limiting toxicities and no observed side effects attributable to the enzyme, and established the dose for subsequent clinical trials, therefore achieving the pre-defined primary objective of the study. In addition, there were no neutralizing antibodies to rHuPH20 detected and the plasma concentration of mitomycin was either non-measureable or negligible and well below the threshold that may be predictive for myelosuppression (a decrease in bone marrow activity, resulting in fewer red blood cells, white blood cells, and platelets).

The study also provided support for future pivotal trial development that will incorporate the highest combination dose studied in the current trial, mitomycin plus 800,000 Units of rHuPH20. Commenting on the results, Richard C. Yocum, M.D., Vice President of Clinical Development and Medical Affairs at Halozyme stated, "We are pleased the study demonstrated that Chemophase was well-tolerated and produced no dose-limi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
5. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic cancers and women,s health, has appointed ... and Managed Markets. Ms. Bauzon has a ... expanding payer coverage for laboratory services companies. She has ... with PerkinElmer, Inc., where she held the position of ...
(Date:8/21/2014)... 21, 2014  Publicis Groupe customer engagement agency ... Partner and Healthcare Industry Group Leader, has been featured ... the most inspiring people in the life-sciences industry. Those ... and development, marketing, technology, creativity, strategy and medicine. ... a partner in its leading Rosetta Consulting practice. In ...
(Date:8/21/2014)... CHARLOTTE, N.C. , Aug. 21, 2014 /PRNewswire-iReach/ ... Home Medical Equipment, Inc. for the third straight ... annual Inc. 500|5000, an exclusive ranking of the ... most comprehensive look at the most important segment ... Yelp, Pandora, Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... Kendle (Nasdaq: KNDL ), a leading, global ... of a planned succession Senior Vice President and COO Stephen ... Chairman and CEO Candace Kendle, PharmD, will continue to serve ... COO from Dr. Cutler will be Jamie Macdonald, who brings ...
... 14, 2011 Zoledronic acid (sold by Novartis as ... Tumor Metastasis, and Paget,s Disease with sales of $2 ... such as post-dose syndrome and osteonecrosis of the jaw. ... the administration of Zoledronic acid in combination with another ...
Cached Medicine Technology:Kendle Announces CEO Succession Plan, Promotes Stephen Cutler, PhD, to President and CEO 2Kendle Announces CEO Succession Plan, Promotes Stephen Cutler, PhD, to President and CEO 3Kendle Announces CEO Succession Plan, Promotes Stephen Cutler, PhD, to President and CEO 4ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination 2
(Date:8/21/2014)... 2014 Improv performers from Fun House ... dementia at Silverado Turtle Creek memory care community in ... entertainers ranging from ages 10 to 16, delivers a ... 40-minute set. The troupe's philosophy is that improv is ... them to touch audiences regardless of their circumstance — ...
(Date:8/21/2014)... 21, 2014 (HealthDay News) -- Black mothers are less ... here,s one possible reason why: Hospitals in neighborhoods with ... those in areas with more white residents, a U.S. ... are much less common in medical centers where the ... U.S. Centers for Disease Control and Prevention reported Thursday. ...
(Date:8/21/2014)... 2014 The W. Montague Cobb/ ... a national voice in the elimination of health ... during the 112th National Medical Association’s (NMA) Annual ... , John Ruffin, Ph.D, former Director of the ... whose life-long career and innovations have had a ...
(Date:8/21/2014)... physicians in rural communities do not routinely screen ... Penn State medical and public health researchers. Rural ... limited resources if they seek help., "Rural health ... said Jennifer S. McCall-Hosenfeld, a primary care physician ... sciences, Penn State College of Medicine. "However, in ...
(Date:8/21/2014)... The report "Industrial Flue Gas ... System (FGD, DeNOx, Particulate Control, Mercury Control) by ... & Others) - Global Trends & Forecasts to ... gas treatment systems & services market with analysis ... terms of value. The industrial flue gas treatment ...
Breaking Medicine News(10 mins):Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4
... of Vermont will elevate the state to being the second ... health-care insurance// , which will cover nearly 96 percent of ... definitely relief for the 46 million Americans who are not ... and costs of insurance premium showing an upward trend, this ...
... getting dirtier despite promises, claimed patients in a survey despite ... ,The annual NHS patients survey has found high levels of ... questions were asked of the 80,000 people who took part ... ward ha been ‘very clean’ as compared to 56% in ...
... Scotland's health minister Andy Kerr said that the NHS staff ... latest statistics on NHS waiting times// as the "best ever". ... had reduced from 12 to 6 months. ,Reports ... number of outpatients and inpatient day cases with an 18-week ...
... cases of diarrhoea in Ranchi, the Jharkhand Health department ... with the disease. // ,'We have equipped ... free-of-cost treatment to patients,' Health and Family Welfare's joint ... patients to avail free treatment at the hospital instead ...
... world , including India, must face the challenges of ... their citizens get access to effective healthcare // , ... medical expenses, a new World Bank report said. ... to cope with sharply rising costs even while countries ...
... by the Indian Medical Association, the junior doctors of ... colleges today struck work launching a one-day strike. ... and government dental hospitals were 'totally shut down', emergency ... Assoication, BMC told PTI., ,'We will watch the ...
Cached Medicine News:Health News:Quality Of NHS Hospitals Getting Dirtier Despite Promises 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 3
...
...
... Bigliani/Flatow shoulder allows for the restoration ... of shoulder replacement surgery. Backed by ... decades of experience, the Bigliani/Flatow Shoulder ... natural shoulder's mobility, balance, and stability ...
... Simplified shoulder replacement system designed ... implantation. Multiple component combinations for ... revision length porous titanium stems. ... of Bi-Polar shell diameters and ...
Medicine Products: